Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small- Cell Lung Cancer: A Reviewde Moraes Junior RM, Mota GS, Carolino MLO and Kerche-Silva LE*
Medical School of Presidente Prudente, Western Sao Paulo University, Brazil
- *Corresponding Author:
- Kerche-Silva LE
Medical School of Presidente Prudente
Western Sao Paulo University, Jose Bongiovani St
700, 19050-920, Presidente Prudente-SP, Brazil
E-mail: [email protected]
Received date: May 15, 2017; Accepted date: May 23, 2017; Published date: May 30, 2017
Citation: de Moraes JRM, Mota GS, Carolino MLO, Kerche-Silva LE (2017) Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small-Cell Lung Cancer: A Review. J Lung Cancer Diagn Treat 2:115.
Copyright: © 2017 de Moraes, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Small-cell lung cancer (SCLC) is one of the deadliest type of cancer with fast tumor growth and rapid metastatic dissemination. The most common genetic modifications associated with SCLC is connected to tumor suppressor and oncogenic genes, genes that control the cycle arrest of the cells. Standard treatment for SCLC is a combination of drugs such as cisplatin and etoposide and sometimes radiotherapy of the chest can be used. But these treatments have not been sufficient to decrease dead rate in SCLC patients and new drugs have been studied, specially humanized monoclonal antibodies (mAb). Therefore, the aim of this work is to review the main genetic alterations in SCLC and the mAb that has been tested to improve life expectancy in these patients.